Healthcare Sector Articles Healthcare Sector Articles - Page 2 March 12, 2026 1:24 PM ETWhy 2 Small Biotechs May Hold the Key to New Cancer TreatmentsNathan ReiffNASDAQ:IOVANASDAQ:IBRXRead Why 2 Small Biotechs May Hold the Key to New Cancer TreatmentsMarch 10, 2026 12:03 PM ETPatience Pays: Hims & Hers Surges on News of Novo Nordisk DealJordan ChusslerNYSE:HIMSNYSE:NVORead Patience Pays: Hims & Hers Surges on News of Novo Nordisk DealMarch 8, 2026 6:00 AM ETThe Aging of America Could Make HCA Healthcare a Long-Term WinnerNathan ReiffNYSE:HCARead The Aging of America Could Make HCA Healthcare a Long-Term WinnerMarch 7, 2026 6:49 AM ET3 Undervalued Names Too Cheap to IgnoreNathan ReiffNYSE:MRKNASDAQ:CPBNYSE:USFDRead 3 Undervalued Names Too Cheap to IgnoreMarch 6, 2026 6:25 AM ETThese 3 Cash Flow Machines Provide Stability in Uncertain MarketsNathan ReiffNASDAQ:GILDNYSE:ABBVNYSE:VRead These 3 Cash Flow Machines Provide Stability in Uncertain MarketsFebruary 28, 2026 5:00 AM ETMarketBeat Week in Review – 02/23 - 02/27MarketBeat StaffNYSE:KONASDAQ:NVDANASDAQ:TEMRead MarketBeat Week in Review – 02/23 - 02/27February 27, 2026 5:24 PM ETAfter a Near 50% Drop, Tempus AI Could Be Ripe for a ReboundLeo MillerNASDAQ:TEMRead After a Near 50% Drop, Tempus AI Could Be Ripe for a ReboundFebruary 26, 2026 12:37 PM ETViking Therapeutics: The High-Stakes Weight Loss ContenderJeffrey Neal JohnsonNYSE:NVONYSE:LLYNASDAQ:VKTXRead Viking Therapeutics: The High-Stakes Weight Loss ContenderFebruary 25, 2026 4:23 PM ETTempus AI Sold Off After a Beat—But the Rebound Case Is BuildingThomas HughesNASDAQ:TEMRead Tempus AI Sold Off After a Beat—But the Rebound Case Is BuildingFebruary 24, 2026 2:37 PM ETBoring Is Beautiful: Why Johnson & Johnson Is Beating the Tech SectorJeffrey Neal JohnsonNYSE:JNJRead Boring Is Beautiful: Why Johnson & Johnson Is Beating the Tech SectorFebruary 23, 2026 10:24 AM ETHinge Health’s AI Moat Might Be Its Patient Movement DataLeo MillerNYSE:HNGERead Hinge Health’s AI Moat Might Be Its Patient Movement DataFebruary 21, 2026 8:03 AM ETHims & Hers in Free Fall: Why Analysts See Nearly 150% UpsideJordan ChusslerNYSE:HIMSNYSE:NVORead Hims & Hers in Free Fall: Why Analysts See Nearly 150% UpsideFebruary 20, 2026 9:14 AM ETMagic Mushrooms, Hard Cash: Compass Pathways’ Trial Win, Fast RaiseJeffrey Neal JohnsonNASDAQ:CMPSNASDAQ:HELPRead Magic Mushrooms, Hard Cash: Compass Pathways’ Trial Win, Fast RaiseFebruary 19, 2026 10:32 AM ETCRISPR Therapeutics Gains After Earnings as Pipeline Hope GrowsChris MarkochNASDAQ:CRSPNASDAQ:VRTXNYSE:MSRead CRISPR Therapeutics Gains After Earnings as Pipeline Hope GrowsFebruary 17, 2026 4:18 PM ETMedtronic’s “Textbook” Reversal: How High Can It Really Go in 2026?Thomas HughesNYSE:MDTRead Medtronic’s “Textbook” Reversal: How High Can It Really Go in 2026? Page 2 of 2 ‹ Most Recent12 More Articles by TopicArticle TopicsAll ArticlesAIAnalyst RatingsBiotechCongressional TradingConsumer Discretionary SectorConsumer Staples SectorDefenseDividendEarningsElectric VehicleEnergy SectorETFFinance SectorHealthcare SectorIndustrial SectorInsider TradingIPOMacroMaterials SectorMergers & AcquisitionsQuantum ComputingRare Earth MineralsSemiconductorShort InterestSpaceStock IdeaStock MarketTechnology SectorInstant Alert TopicsAll Instant AlertsAnalystCongressional TradesConsensusCorporate BuybackCorporate Event TranscriptStock ListDividendEarningsEarnings PreviewEarnings Transcript HighlightsEstimatesGuidanceInsider TradeLockup ExpirationMarketBeat List ArticlesOptionsPriceSEC FilingStock Split Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
